-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction The advancement of medical technology drives the development and application of anti-tumor drugs into the "fast lane".
New anti-tumor drugs represented by immune checkpoint inhibitors (ICIs) continue to "refresh" the survival benefit record of tumor patients
.
While strengthening the management of pharmaceutical affairs in medical institutions, the National Health Commission has actively formulated and issued the "Guiding Principles for the Clinical Application of New Anti-tumor Drugs" to promote the standardized clinical use of new anti-tumor drugs and provide more patients with high-quality medical services.
Improve patient survival benefit
.
Yimaitong invited Professor Fang Luo from the Pharmacy Department of the Cancer Hospital of the University of Chinese Academy of Sciences to share his experience and insights in the management of anti-tumor drugs
.
Multi-dimensional consideration of standardized medications and comprehensive improvement of patient medical quality Professor Fang Luo pointed out that in recent years, the growth of new anti-tumor drugs has not only brought more and better choices for clinical treatment, but also proposed reasonable and standardized medications for clinical treatment.
A whole new challenge
.
As new anti-tumor drugs are unique in terms of treatment, safety, and economy, clinicians and pharmacists should focus on the use of new anti-tumor drugs beyond the indications, monitoring of adverse reactions, and the therapeutic value of patients, so as to improve the clinical use of tumor patients Standardize and improve the treatment benefits of patients
.
Be cautious when using off-label drugs.
With the continuous exploration of tumor evidence-based medicine research, the use of high-level evidence-based medicine continues to emerge, and is recommended by major domestic and foreign authoritative guidelines, such as the Chinese Society of Clinical Oncology (CSCO) guidelines
.
However, due to the fact that the drug inserts lag behind clinical practice, the use of some drugs with high-level evidence-based medical evidence has not been clearly stipulated in the drug inserts in time
.
Therefore, tumor diagnosis and treatment guidelines have become an important basis for clinical decision-making and program implementation, which also makes it difficult to avoid over-instructions of anti-tumor drugs
.
Professor Fang Luo emphasized that the phenomenon of out-of-specification use of anti-tumor drugs is common, but it does not mean that it is reasonable
.
Clinicians and pharmacists should strictly follow the relevant management systems and technical specifications to conduct super-indication treatments and closely monitor the clinical manifestations of patients
.
Pay attention to adverse reaction monitoring In terms of adverse reaction monitoring, Professor Fang Luo pointed out that new drugs are constantly on the market, especially the lack of awareness of the adverse reactions of some new anti-tumor drugs, which has caused clinicians and pharmacists to pay relatively little attention to their adverse reactions
.
However, in actual clinical applications, new anti-tumor drugs can also cause fatal adverse reactions.
For example, anti-angiogenic drugs can cause gastric perforation
.
In addition, because new anti-tumor drugs have not undergone extensive clinical verification and safety tests, there may also be potential safety hazards.
Therefore, clinicians and pharmacists should focus on monitoring drug adverse reactions to further improve relevant data and improve drug safety
.
Comprehensive consideration of pharmacoeconomics In addition to safety and effectiveness, clinicians and pharmacists should also comprehensively consider the patient’s own economic status, pay attention to the value of treatment for cancer patients, and enable patients to obtain longer survival times and longer survival times under the premise of limited treatment costs.
For better quality of life, give priority to drugs with cost-effectiveness advantages
.
In addition, Professor Fang Luo also emphasized that precise identification of beneficiaries, drug management for patients at home, and use of drugs outside the hospital are also important considerations in the clinical medication specifications for cancer patients
.
With the promulgation of national policies, the clinical medication specifications for cancer patients have risen to the level of quality control, which has laid a good foundation for improving the treatment benefits of patients
.
Improve drug data to prevent adverse reactions.
In recent years, new anti-tumor drugs represented by immunotherapy have been widely used in clinics and have brought "revolutionary" changes to tumor treatment
.
Immunotherapy has become the fourth-largest anti-tumor drug treatment model after chemotherapy, targeted, and endocrine therapy
.
Professor Fang Luo said that since the application of Coley Toxin, immunotherapy has a history of 100 years, and many new immunotherapies have evolved, such as ICIs, adoptive cell therapy, and oncolytic viruses, but they are used as independent "weapons" in tumor treatment.
But a few years
.
Therefore, compared with chemotherapy and targeted drugs, clinicians and pharmacists have not yet fully understood its safety
.
Clinicians and pharmacists should strengthen drug evaluation and safety monitoring, improve the research system and real-world data, in order to strengthen the awareness of adverse reactions of new immunological drugs, and improve the ability to prevent and handle adverse reactions
.
Taking oncolytic virus as an example, although the most common adverse reactions are flu-like symptoms and local reactions at the injection site, monitoring and prevention of adverse reactions are very important
.
Exploring the development direction of the pharmacy department and improving the treatment benefits of patients As an important part of the medical technology system, the pharmacy department builds a communication bridge between patients and clinical departments, and in terms of clinical application of new anti-tumor drugs and improving patient survival benefits Plays an important role
.
Professor Fang Luo said that the homogeneity of patients enrolled in drug clinical research is relatively high, but in real-world applications, there are significant differences in physical fitness between patients, and the medication situation is more complicated, so it is difficult to generalize the dosage, efficacy and safety of drugs.
.
Therefore, dosage research and monitoring based on the metabolic behavior of patients, drug exposure in the body, drug interactions and other factors are one of the important development directions of the pharmacy department to ensure that the drug fully exerts its anti-tumor effect within the treatment window and reduces toxic and side effects.
Happened
.
In addition, due to the particularity of the tumor, the pharmacy team should focus on the patient's home medication and doctor-patient communication
.
Therefore, the Pharmacy Department of Cancer Hospital Affiliated to the Chinese Academy of Sciences has established a cancer patient management platform, and relying on the rich clinical pharmacist resources in the hospital to manage cancer patients’ home medications and popularize science education, increase communication and exchanges between doctors and patients, and improve the safety of patients’ home medications.
, Compliance, and effectively improve the treatment benefits of patients
.
New anti-tumor drugs represented by immune checkpoint inhibitors (ICIs) continue to "refresh" the survival benefit record of tumor patients
.
While strengthening the management of pharmaceutical affairs in medical institutions, the National Health Commission has actively formulated and issued the "Guiding Principles for the Clinical Application of New Anti-tumor Drugs" to promote the standardized clinical use of new anti-tumor drugs and provide more patients with high-quality medical services.
Improve patient survival benefit
.
Yimaitong invited Professor Fang Luo from the Pharmacy Department of the Cancer Hospital of the University of Chinese Academy of Sciences to share his experience and insights in the management of anti-tumor drugs
.
Multi-dimensional consideration of standardized medications and comprehensive improvement of patient medical quality Professor Fang Luo pointed out that in recent years, the growth of new anti-tumor drugs has not only brought more and better choices for clinical treatment, but also proposed reasonable and standardized medications for clinical treatment.
A whole new challenge
.
As new anti-tumor drugs are unique in terms of treatment, safety, and economy, clinicians and pharmacists should focus on the use of new anti-tumor drugs beyond the indications, monitoring of adverse reactions, and the therapeutic value of patients, so as to improve the clinical use of tumor patients Standardize and improve the treatment benefits of patients
.
Be cautious when using off-label drugs.
With the continuous exploration of tumor evidence-based medicine research, the use of high-level evidence-based medicine continues to emerge, and is recommended by major domestic and foreign authoritative guidelines, such as the Chinese Society of Clinical Oncology (CSCO) guidelines
.
However, due to the fact that the drug inserts lag behind clinical practice, the use of some drugs with high-level evidence-based medical evidence has not been clearly stipulated in the drug inserts in time
.
Therefore, tumor diagnosis and treatment guidelines have become an important basis for clinical decision-making and program implementation, which also makes it difficult to avoid over-instructions of anti-tumor drugs
.
Professor Fang Luo emphasized that the phenomenon of out-of-specification use of anti-tumor drugs is common, but it does not mean that it is reasonable
.
Clinicians and pharmacists should strictly follow the relevant management systems and technical specifications to conduct super-indication treatments and closely monitor the clinical manifestations of patients
.
Pay attention to adverse reaction monitoring In terms of adverse reaction monitoring, Professor Fang Luo pointed out that new drugs are constantly on the market, especially the lack of awareness of the adverse reactions of some new anti-tumor drugs, which has caused clinicians and pharmacists to pay relatively little attention to their adverse reactions
.
However, in actual clinical applications, new anti-tumor drugs can also cause fatal adverse reactions.
For example, anti-angiogenic drugs can cause gastric perforation
.
In addition, because new anti-tumor drugs have not undergone extensive clinical verification and safety tests, there may also be potential safety hazards.
Therefore, clinicians and pharmacists should focus on monitoring drug adverse reactions to further improve relevant data and improve drug safety
.
Comprehensive consideration of pharmacoeconomics In addition to safety and effectiveness, clinicians and pharmacists should also comprehensively consider the patient’s own economic status, pay attention to the value of treatment for cancer patients, and enable patients to obtain longer survival times and longer survival times under the premise of limited treatment costs.
For better quality of life, give priority to drugs with cost-effectiveness advantages
.
In addition, Professor Fang Luo also emphasized that precise identification of beneficiaries, drug management for patients at home, and use of drugs outside the hospital are also important considerations in the clinical medication specifications for cancer patients
.
With the promulgation of national policies, the clinical medication specifications for cancer patients have risen to the level of quality control, which has laid a good foundation for improving the treatment benefits of patients
.
Improve drug data to prevent adverse reactions.
In recent years, new anti-tumor drugs represented by immunotherapy have been widely used in clinics and have brought "revolutionary" changes to tumor treatment
.
Immunotherapy has become the fourth-largest anti-tumor drug treatment model after chemotherapy, targeted, and endocrine therapy
.
Professor Fang Luo said that since the application of Coley Toxin, immunotherapy has a history of 100 years, and many new immunotherapies have evolved, such as ICIs, adoptive cell therapy, and oncolytic viruses, but they are used as independent "weapons" in tumor treatment.
But a few years
.
Therefore, compared with chemotherapy and targeted drugs, clinicians and pharmacists have not yet fully understood its safety
.
Clinicians and pharmacists should strengthen drug evaluation and safety monitoring, improve the research system and real-world data, in order to strengthen the awareness of adverse reactions of new immunological drugs, and improve the ability to prevent and handle adverse reactions
.
Taking oncolytic virus as an example, although the most common adverse reactions are flu-like symptoms and local reactions at the injection site, monitoring and prevention of adverse reactions are very important
.
Exploring the development direction of the pharmacy department and improving the treatment benefits of patients As an important part of the medical technology system, the pharmacy department builds a communication bridge between patients and clinical departments, and in terms of clinical application of new anti-tumor drugs and improving patient survival benefits Plays an important role
.
Professor Fang Luo said that the homogeneity of patients enrolled in drug clinical research is relatively high, but in real-world applications, there are significant differences in physical fitness between patients, and the medication situation is more complicated, so it is difficult to generalize the dosage, efficacy and safety of drugs.
.
Therefore, dosage research and monitoring based on the metabolic behavior of patients, drug exposure in the body, drug interactions and other factors are one of the important development directions of the pharmacy department to ensure that the drug fully exerts its anti-tumor effect within the treatment window and reduces toxic and side effects.
Happened
.
In addition, due to the particularity of the tumor, the pharmacy team should focus on the patient's home medication and doctor-patient communication
.
Therefore, the Pharmacy Department of Cancer Hospital Affiliated to the Chinese Academy of Sciences has established a cancer patient management platform, and relying on the rich clinical pharmacist resources in the hospital to manage cancer patients’ home medications and popularize science education, increase communication and exchanges between doctors and patients, and improve the safety of patients’ home medications.
, Compliance, and effectively improve the treatment benefits of patients
.
